Ebronucimab vs Ongericimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Marketed by Hubei Jumpcan Pharmaceutical and partners
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)
Result source: NCT05255094
Ongericimab · Junshida
Marketed by Shanghai Junshi Bioscience
NCT04781114 · Phase 3 · completed
This large, randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint was clearly met: both ongericimab dose regimens produced large, statistically significant reductions in LDL cholesterol versus placebo.
Reported efficacy
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and week 24): Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001) (met)
Result source: NCT05325203
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ebronucimab | Ongericimab |
|---|---|---|
| LDL-C, % change | —Not posted · NCT05260411 | —Not posted · NCT05532800 |
| Non-HDL-C, % change | —Not posted · NCT05260411 | —Not posted · NCT05532800 |
| ApoB, % change | —Not posted · NCT05260411 | —Not posted · NCT05532800 |
| Lp(a), % change | —Not posted · NCT05260411 | —Not posted · NCT05532800 |
| 3-point MACE (% with event) | —Not posted · NCT05260411 | —Not posted · NCT05532800 |
LDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Ongericimab
- —Not posted · NCT05532800
Non-HDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- Ongericimab
- —Not posted · NCT05532800
ApoB, % change
- Ebronucimab
- —Not posted · NCT05260411
- Ongericimab
- —Not posted · NCT05532800
Lp(a), % change
- Ebronucimab
- —Not posted · NCT05260411
- Ongericimab
- —Not posted · NCT05532800
3-point MACE (% with event)
- Ebronucimab
- —Not posted · NCT05260411
- Ongericimab
- —Not posted · NCT05532800
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint
Coverage. Ebronucimab: 1 of 1 rows · Ongericimab: 1 of 1 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ebronucimab | Ongericimab |
|---|---|---|
| LDL-C percent change · % of baseline No placebo or comparator arm | -59.13% @ 12wk450 mg Q4Wa,b,c NCT05255094 · Phase 3 · sponsor-reported, not registry data show 1 more dose-60.43% @ 12wk150 mg Q2W NCT05255094 · Phase 3 · sponsor-reported, not registry data | -71.1% @ 12wka,b,c NCT05532800 · Phase 3 · sponsor-reported, not registry data show 1 more dose-72.7% @ 12wk NCT05532800 · Phase 3 · sponsor-reported, not registry data |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Ongericimab's landscape